scholarly journals Circulating tumor DNA as a marker of residual tumor in colon cancer

2018 ◽  
Vol 8 (3) ◽  
pp. 11-16
Author(s):  
M. Yu. Fedyanin ◽  
Kh. Kh.-M. Elsnukaeva ◽  
V. A. Aliev ◽  
T. S. Ayrapetyan ◽  
A. V. Polyakov ◽  
...  
Keyword(s):  
Colon Cancer ◽  
Malignant Tumors ◽  
Malignant Neoplasm ◽  
Residual Tumor ◽  
Circulating Tumor Dna ◽  
Theoretical Background ◽  
National Medical ◽  
Fundamental Medicine ◽  
Tumor Dna ◽  
Predict Disease Progression

Colon cancer is the 3rdmost common malignant neoplasm and the 4thleading cause of mortality from them. The majority of patients are diagnosed at stages II–IV, which indicates the need for markers that can predict disease progression, especially after surgical treatment. Recently, there has been a growing interest in exploring circulating tumor DNA as a marker of residual tumor in colon cancer. In 2018, the N.N. Blokhin National Medical Research Center of Oncology together with the Institute of Chemical Biology and Fundamental Medicine under the coordination of the Center for Strategic Planning and Management of Biomedical Health Risks initiated a research project entitled “Development of an assay for the diagnosis of various malignant tumors and treatment efficacy monitoring based on the analysis of circulating tumor DNA from patient blood”. This article provides a theoretical background for the project and a report on its progress made so far.

ctDNA as a prognostic factor in operable colon cancer patients: a systematic review and meta-analysis

2020 ◽  
Author(s):  
Emre Yekedüz ◽  
Elif Berna Köksoy ◽  
Hakan Akbulut ◽  
Yüksel Ürün ◽  
Güngör Utkan
Keyword(s):  
Colon Cancer ◽  
Prognostic Factor ◽  
Cancer Patients ◽  
Meta Analysis ◽  
Circulating Tumor Dna ◽  
Random Effects Model ◽  
Inverse Variance ◽  
Increased Risk ◽  
Significant Step ◽  
Tumor Dna

Aim: Using circulating tumor DNA (ctDNA) instead of historical clinicopathological factors to select patients for adjuvant chemotherapy (ACT) may reduce inappropriate therapy. Material & methods: MEDLINE was searched on March 31, 2020. Studies, including data related to the prognostic value of ctDNA in the colon cancer patients after surgery and after ACT, were included. The generic inverse-variance method with a random-effects model was used for meta-analysis. Results: Four studies were included for this meta-analysis. ctDNA-positive colon cancer patients after surgery and ACT had a significantly increased risk of recurrence compared with ctDNA-negative patients. Conclusions: ctDNA is an independent prognostic factor, and this meta-analysis is a significant step for using ctDNA instead of historical prognostic factors in the adjuvant setting.

scholarly journals Prognostic value of circulating tumor DNA in patients with colon cancer: Systematic review

PLoS ONE ◽  
2017 ◽  
Vol 12 (2) ◽  
pp. e0171991 ◽  
Author(s):  
Gaowei Fan ◽  
Kuo Zhang ◽  
Xin Yang ◽  
Jiansheng Ding ◽  
Zujian Wang ◽  
...  
Keyword(s):  
Systematic Review ◽  
Colon Cancer ◽  
Prognostic Value ◽  
Circulating Tumor Dna ◽  
Tumor Dna

scholarly journals Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer

2016 ◽  
Vol 8 (346) ◽  
pp. 346ra92-346ra92 ◽  
Author(s):  
Jeanne Tie ◽  
Yuxuan Wang ◽  
Cristian Tomasetti ◽  
Lu Li ◽  
Simeon Springer ◽  
...  
Keyword(s):  
Colon Cancer ◽  
Minimal Residual Disease ◽  
Dna Analysis ◽  
Residual Disease ◽  
Circulating Tumor Dna ◽  
Stage Ii ◽  
Stage Ii Colon Cancer ◽  
Tumor Dna ◽  
Minimal Residual

Circulating tumor cells and circulating tumor DNA in colon cancer

2016 ◽  
Vol 9 (2) ◽  
pp. 88-92
Author(s):  
Mikhail Fedyanin ◽  
Elizaveta Polyanskaya ◽  
Sergei Tjulandin
Keyword(s):  
Colon Cancer ◽  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Circulating Tumor Dna ◽  
Tumor Dna

scholarly journals Circulating tumor DNA guided adjuvant chemotherapy in stage II colon cancer (MEDOCC-CrEATE): study protocol for a trial within a cohort study

BMC Cancer ◽  
2020 ◽  
Vol 20 (1) ◽  
Author(s):  
S. J. Schraa ◽  
◽  
K. L. van Rooijen ◽  
D. E. W. van der Kruijssen ◽  
C. Rubio Alarcón ◽  
...  
Keyword(s):  
Colon Cancer ◽  
Cohort Study ◽  
Adjuvant Chemotherapy ◽  
Study Protocol ◽  
Circulating Tumor Dna ◽  
Stage Ii ◽  
Stage Ii Colon Cancer ◽  
Tumor Dna

Phase II/III study of circulating tumor DNA as a predictive biomarker in adjuvant chemotherapy in patients with stage II colon cancer:NRG-GI005 (COBRA).

2021 ◽  
Vol 39 (3_suppl) ◽  
pp. TPS148-TPS148
Author(s):  
Van K. Morris ◽  
Greg Yothers ◽  
Scott Kopetz ◽  
Samuel A. Jacobs ◽  
Peter C. Lucas ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Colon Cancer ◽  
High Risk ◽  
Adjuvant Chemotherapy ◽  
Phase Ii ◽  
Predictive Biomarkers ◽  
Circulating Tumor Dna ◽  
Stage Ii ◽  
Phase Iii ◽  
Tumor Dna

TPS148 Background: There are currently no validated predictive biomarkers for stage II resected colon cancer (CC) after adjuvant chemotherapy. However, circulating tumor DNA (ctDNA) that is shed into the bloodstream represents a highly specific and sensitive approach for identifying microscopic or residual tumor cells. For patients (pts) with CC, the detection of ctDNA is associated with persistent disease after resection and may outperform traditional clinical and pathological features as a prognostic factor to assess risk for recurrence. We hypothesize that for pts whose stage II colon cancer has been resected and who have no traditional high-risk features, a positive ctDNA status may identify those who will benefit from adjuvant chemotherapy. Methods: In this prospective phase II/III clinical trial, pts (N=1,408) with resected stage II CC without traditional high-risk features and whom the evaluating oncologist deems suitable for no adjuvant chemotherapy will be randomized 1:1 into 2 arms:standard-of-care/observation (Arm A), or prospective testing for ctDNA (Arm B). Postoperative blood will be analyzed for ctDNA with the GuardantHealth LUNAR panel, covering CC-relevant mutations and CC-specific methylation profiling. Pts in Arm B with ctDNA detected will be treated with 6 months of adjuvant (FOLFOX) chemotherapy. For all pts in Arm A, ctDNA status will be analyzed retrospectively at the time of endpoint analysis. The primary endpoints are clearance of ctDNA with adjuvant chemotherapy (phase II) and recurrence-free survival (RFS) for “ctDNA-detected” pts treated with or without adjuvant chemotherapy (phase III). Secondary endpoints will include time-to-event outcomes (OS, RFS, TTR) by ctDNA marker status and treatment, prevalence of detectable ctDNA in stage II CC, and rates of compliance with assigned intervention. Archived normal and matched tumor and blood samples will be collected for exploratory correlative research. The trial is actively accruing towards the phase II endpoint across all US and Canadian cooperative groups. Support:U10-CA-180868, -180822; UG1CA-189867; GuardantHealth. Clinical trial information: NCT04068103.

Abstract 3096: Liquid biopsy cell-free circulating tumor DNA as prognostic biomarker for stage III colon cancer patients

2020 ◽  
Author(s):  
Carmen Rubio Alarcón ◽  
Dave E. van der Kruijssen ◽  
Lana Meiqari ◽  
Linda J. Bosch ◽  
John K. Simmons ◽  
...  
Keyword(s):  
Colon Cancer ◽  
Cancer Patients ◽  
Liquid Biopsy ◽  
Prognostic Biomarker ◽  
Circulating Tumor Dna ◽  
Stage Iii ◽  
Stage Iii Colon Cancer ◽  
Tumor Dna
Sign in / Sign up

Export Citation Format

Share Document